Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 1999

View Archived Issues

U.S. DOD funds study of HupA as neuroprotective agent

High-dose tirilazad mesilate assessed in women with aneurysmal subarachnoid hemorrhage

Celgene reports potent, specific immune responses for thalidomide analogues

Cortecs provides research and development update

Oxford BioMedica and Modex Therapeutiques to develop diabetes therapy

Columbia Laboratories finalizes Crinone license transfer

Phase I trials evaluating J695 now under way

Nastech completes phase III testing of intranasal scopolamine

Perstorp subsidiary merges with Endogen

Bristol-Myers Squibb extends antiinfective collaboration with Cubist Pharmaceuticals

Solvay completes financing for Unimed tender offer, extends tender offer

Disappointing phase II trial results for Ergoset in the treatment of obesity

Structurally novel antitumor and immunosuppressive compounds from Klinge

U.S. patent covers Immucon's novel male contraceptive vaccine technology

Novel gabapentin analogues with anticonvulsant and/or analgesic effects

Neurocrine Biosciences reacquires rights to novel MS treatment

Cytokine suppressors for immune disorders developed at SS Pharm.

Indena presents novel paclitaxel derivatives with excellent antitumor activity

New MMP inhibitors, their preparation and use described by Pfizer scientists

Yoshitomi describes potent, selective tryptase inhibitors

Promising new atypical antipsychotic agent with positive effects on cognition: RGH-1756

WHO develops pyronaridine, an orally active agent for treating chloroquine-resistant malaria

Collaborative antipsychotic R&D yields interesting candidates for development

Inhibitors of protein geranylgeranylation developed at Baldacci as antitumor agents

Roche to develop and market Trimeris's HIV fusion inhibitors

More on PEDF: protein also has ophthalmic indications

Nonsteroidal Rx for atopic dermatitis enters late-stage clinical trials in U.S.

SomatoKine given orphan drug status as treatment of severe burns

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...